about
Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based DesignNeutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorEnhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus InfectionEliminating antibody polyreactivity through addition of N-linked glycosylation.Activation and lysis of human CD4 cells latently infected with HIV-1Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional PotencyHuman Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaquesA single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.Use of broadly neutralizing antibodies for HIV-1 prevention.Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN.Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.Afferent and efferent interfaces of lymph nodes are distinguished by expression of lymphatic endothelial markers and chemokines.Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies.Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection.P13-07 LB. A human blocking antibody to CCR5 partially protects against lentiviral infection in non-human primates.Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.Accumulation of follicular CD8+ T cells in pathogenic SIV infection.Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopesAnti-HIV-1 Antibodies: An UpdateDelayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaquesSingle-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
P50
Q27644646-A7BE7745-209C-4017-8BC4-51F601A2850FQ27684529-EB2BF03F-D7AA-4F0D-8C32-D3FB43BC72F6Q34593860-F51EC814-5C26-4D61-A993-3ECD0D070562Q35612850-B5D268FF-262F-40F9-8B18-DDDDFCAC5246Q35641234-A8A0A91D-6073-4B41-83D8-007B502192E4Q35684786-6CF05AF2-E4A8-48A3-A9A7-B2626F78D3D9Q36250921-1CEBA0B4-BFE1-4C08-890F-BF1B178888C1Q36334359-C572EA7C-2D57-4E93-9B29-CC041D34A87EQ36433894-5100A2A3-163E-4712-9160-D73B0EA1F7FFQ36481483-3B8C2E4D-6F65-4281-960A-0BE39789B0F6Q37171570-24ABB727-E8CD-48B1-A852-3A4309632368Q37450695-A130EBC1-0CF7-453E-93B4-C6BD59D885E2Q38645979-DC1A8939-28DB-4914-B5DB-DC9ADEBFD994Q38764543-D7C08CC7-09F8-4614-9B4C-0D889664C0E2Q40002946-04FCE059-5E62-42FA-81F7-02B17DD20413Q40055103-2B74BABA-BB17-48A3-A4E5-AA2121F39B55Q40164206-E5AF619D-91BC-4C6A-8086-823383BF99D9Q40187584-32084A19-6CBA-4DA8-883D-23BB93E67593Q40366328-0C111FCA-E35C-49DB-932A-82A67471B871Q41019767-ECA4C4BA-00B6-4097-9F0C-F78CB601B849Q41933491-EFF530B1-4227-4D17-90DA-CF3D4AC68617Q45757133-C805CC76-5924-4E4D-9DF3-44DBEB817807Q50306276-8A978F14-0D68-40F2-8D08-61B3F272C0CCQ53689028-CC02EAFA-72BE-4E39-BCEE-3AB39774C473Q54230395-44F2C96C-6701-4F87-95AE-AAFA7339C40EQ54234277-45332F94-BA0C-4C04-AB5D-8BE8238EDE54Q64082353-F11220B5-80FE-40C3-8F97-B1B5A021D3A3Q90173784-417CBC86-13DA-4D4E-949E-4406942AE716Q91983265-837D17D8-949B-4EC7-9BF3-9268AE057C02Q92480393-91EB3867-51B8-4111-B0E8-600ED55C125B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Amarendra Pegu
@ast
Amarendra Pegu
@en
Amarendra Pegu
@es
Amarendra Pegu
@nl
Amarendra Pegu
@sl
type
label
Amarendra Pegu
@ast
Amarendra Pegu
@en
Amarendra Pegu
@es
Amarendra Pegu
@nl
Amarendra Pegu
@sl
prefLabel
Amarendra Pegu
@ast
Amarendra Pegu
@en
Amarendra Pegu
@es
Amarendra Pegu
@nl
Amarendra Pegu
@sl
P106
P1153
35198609100
P21
P31
P496
0000-0003-3564-6453